Abstract:Objective: The aim of this study was to observe the hepatic targeting of Gal-HSA magnetic nanoparticles containing adriamycin and its effect of magnetic field application to targeting distribution of the in vivo. Methods: Abdominal exposure was carried out through a midline abdominal incision. A cannula was inserted into the hepatic artery and fixed up it. Using radioactive tracer technique, Gal-HSA magnetic nanoparticles containing adriamycin and human serum albumin magnetic nanoparticles containing adriamycin were labelled with 125I. 125I Gal-HSA magnetic nanoparticles containing adriamycin and 125I human serum albumin magnetic nanoparticles containing adriamycin were injected into hepatic artery (equivalent dose of free adriamycin 0.5 mg/kg ). At 5, 15, 30, 60, 120 minute after hepatic artery injection.the rat was sacrificed. The liver, kidney, heart, lung, small intestine, spleen and blood was analyzed for 125I-counts. Results: Gal-HSA magnetic nanoparticles containing adriamycin had arrived at maximum uptake quantity in liver after 5 minute, its uptake quantity were 15 054.4 CPM/g. There is remarkable difference between two drugs which distributed in liver, kidney, lung, spleen, heart small intestineand blood (P<0.05). Conclusion: Gal-HSA magnetic nanoparticles containing adriamycin in normal rat liver had remarkable hepatic targeting and good magnetic targeting. Dose which Gal-HSA magnetic nanoparticles containing adriamycin injected mainly distributed in liver.